Latest Whitepapers

Rather than choosing between the detail of single-cell RNA sequencing and the in situ capabilities of conventional immunohistochemistry, spatial phenotyping allow you to visualize and quantify dozens of biomarkers in a single tissue sample while maintaining cellular and sub-cellular detail.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Studying the tumor microenvironment (TME) helps improve our understanding of cancer. Myeloid-derived suppressor cells (MDSCs) exist within the TME and maintain cancer progression.

Determining cell viability is a vital component in many biological experiments and one of the most common methods for this measurement is the trypan blue (TB) exclusion assay.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.

While next-generation sequencing is becoming increasingly routine in cancer research laboratories, it fails to address a number of key genomic drivers or markers of cancer, such as structural variations, DNA methylation and transcript isoforms.

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.

Download this whitepaper to discover how high-throughput flow cytometry can provide quantitative data on binding, antibody internalization and antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and T-cell activation.

Primary antibody labeling simplifies assays, enables multiplexing and eliminates the cross-reactivity seen with secondary antibodies – helping you to streamline your workflow, increase your flexibility and improve reproducibility.

Creating and bringing new drugs to the market can bring huge productivity challenges as the already complex drug development process becomes lengthier and more expensive.